Daniel Bilek

Daniel Bilek

Auto-generated profile, based on publicly available information

Daniel Bilek

Department of Hematooncology, University Hospital Ostrava, Ostrava, Czech Republic

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 March 2026 in Blood
Verified
Journal Article
Open access
TJTomas Jelinek
Tomas Jelinek
DZDavid Zihala
David Zihala
AZAintzane Zabaleta
Aintzane Zabaleta
IKIoannis Kostopoulos
Ioannis Kostopoulos
Ondrej SoucekOndrej Soucek
Ondrej Soucek
RHRoman Hajek
Roman Hajek
Infections remain a challenge during treatment of patients with multiple myeloma (MM) with anti–B-cell maturation antigen (BCMA) and anti–G protein-coupled receptor class C group 5 member D (GPRC5D) bispecific antibodies (bsAbs). However, the mechanism underlying different rates and severity of infections induced by the 2 bsAbs remains poorly understood. Single-cell RNA sequencing of bone marrow (BM) aspirates of 11 patients with MM and 8 healthy donors revealed BCMA expression on mature B cells and, surprisingly, in small pre-B cells within B-cell precursors. GPRC5D expression was restricted to malignant and less to normal plasma cells (PCs). Next-generation flow cytometry immune profiling showed that anti-BCMA bsAbs severely depleted BM mature B cells, from 4.9% to 0% (P< .001), and normal PCs, from 0.17% to <0.0002% (P< .001), during treatment of 62 patients with relapsed MM. This was observed throughout therapy. Additional flow cytometry (n = 31) and single-cell RNA sequencing studies (n = 8) demonstrated that, in contrast to anti-GPRC5D, anti-BCMA bsAbs also depleted immature and small pre-B cells. The MIcγ1 mouse model was used as a negative control of BCMA expression in all stages of the B-cell lineage, confirming no depletion of any B-cell subset after anti-BCMA treatment. In conclusion, we show that although GPRC5D bsAbs selectively target PCs, anti-BCMA bsAbs target both PCs and B cells from the small pre-B stage onward. Our study provides mechanistic insight into the increased infection risk with anti-BCMA therapy and supports individualized bsAb strategies in MM. Moreover, dual targeting of B cells and PCs may have therapeutic potential in other B-cell malignancies or autoimmune diseases.

14 November 2025 in Blood Cancer Discovery
Verified
Journal Article
Open access
ASAnjana Anilkumar Sithara
Anjana Anilkumar Sithara
VKVeronika Kapustová
Veronika Kapustová
DZDavid Zihala
David Zihala
OVOndrej Venglar
Ondrej Venglar
DBDaniel Bilek
Daniel Bilek
TJTomas Jelinek
Tomas Jelinek
Extramedullary multiple myeloma (EMM) is a high-risk feature of multiple myeloma associated with increased resistance to treatments, including modern immunotherapies, and shorter survival. The composition and functional state of immune cells within the EMM tumor microenvironment (TME) remain poorly understood. Using single-cell RNA sequencing, flow cytometry, and spatial transcriptomics, we revealed significant differences in the EMM TME compared with multiple myeloma bone marrow (BM). T and NK cells were verified as the most abundant immune subsets in the EMM TME. Compared with the BM counterparts, we found these tumors to have a significantly reduced effector–to–tumor cell ratio, a significantly lower number of CD4+ T cells, and an increased proportion of regulatory CD16− NK cells. We observed a high proportion of exhausted, tumor-reactive CD8+ T cells in roughly half of EMM tumors. Furthermore, we identified elevated expression of immune checkpoints, such as PD-1 on CD8+ T cells and KLRC1 (NKG2A) on CD16− NK cells. Significance: This study characterizes the TME in EMM lesions and paired BM from patients with multiple myeloma, revealing a high proportion of less cytotoxic CD16− NK cells in EMM tumors and suggesting that direct cell–cell interactions may underlie the CD8+ T-cell exhaustion observed in a subset of these tumors.

4 March 2026
Verified
Other
Open access
ASAnjana Anilkumar Sithara
Anjana Anilkumar Sithara
VKVeronika Kapustová
Veronika Kapustová
DZDavid Zihala
David Zihala
OVOndrej Venglar
Ondrej Venglar
DBDaniel Bilek
Daniel Bilek
TJTomas Jelinek
Tomas Jelinek
Table S3 from Composition and Functional State of T and NK Cells in the Extramedullary Myeloma Tumor Microenvironment

4 March 2026
Verified
Other
Open access
ASAnjana Anilkumar Sithara
Anjana Anilkumar Sithara
VKVeronika Kapustová
Veronika Kapustová
DZDavid Zihala
David Zihala
OVOndrej Venglar
Ondrej Venglar
DBDaniel Bilek
Daniel Bilek
TJTomas Jelinek
Tomas Jelinek
ST indicates comparable distribution of CD16+ and CD16− NK cells across EMM samples. A and B, Estimated spatial cell type abundance of CD16+ and CD16− NK cells, PCs, and T cells in EMM_19 (left) and EMM_23 (right) samples by cell2location. The color scale represents the estimated relative abundance of each cell type in the corresponding spatial spot: Yellow shows higher abundance of the cell type.

4 March 2026
Verified
Other
Open access
PDF file
ASAnjana Anilkumar Sithara
Anjana Anilkumar Sithara
VKVeronika Kapustová
Veronika Kapustová
DZDavid Zihala
David Zihala
OVOndrej Venglar
Ondrej Venglar
DBDaniel Bilek
Daniel Bilek
TJTomas Jelinek
Tomas Jelinek
Median cytotoxicity and exhaustion scores of CD8+ T cells

4 March 2026
Verified
Other
Open access
PDF file
ASAnjana Anilkumar Sithara
Anjana Anilkumar Sithara
VKVeronika Kapustová
Veronika Kapustová
DZDavid Zihala
David Zihala
OVOndrej Venglar
Ondrej Venglar
DBDaniel Bilek
Daniel Bilek
TJTomas Jelinek
Tomas Jelinek
Figure S1 showing correlation between cell types measured by scRNAseq and FCM